AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23799929
Drug: Subcutaneous nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nerve stimulation (SQS) plus optimized medical management
Trial: 20466200
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (2 x 1,200 mg/day for 48 h)
Trial: 18419497
Drug: Planned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatment interruption with nevirapine
Trial: 18419497
Drug: Planned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatment interruption with efavirenz
Trial: 18419497
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (control group)
Trial: 17206976
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of atosiban
Trial: 17206976
Drug: Standard administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard administration of atosiban
Trial: 17206976
Drug: Early atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Early atosiban administration
Trial: 17206976
Drug: Standard atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Standard atosiban administration
Trial: 12545081
Drug: RTV/IDV (100/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV/IDV (100/400 mg bid)
Trial: 12545081
Drug: IDV (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDV (800 mg tid)
Trial: 8781321
Drug: 520-kcal diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 520-kcal diet with less than 2 g fat/d
Trial: 8781321
Drug: 900-kcal diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900-kcal diet with 30 g fat/d (including one 10-g fat meal)
Trial: 1596317
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Methylprednisolone
Trial: 1596317
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml NaCl 0.9%
Trial: 25275230
Drug: Continuous jejunal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous jejunal infusion of levodopa-carbidopa intestinal gel
Trial: 25275230
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral levodopa therapy
Trial: 23207562
Drug: NG solution
RxNorm normalized name: Cleansing Solution
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG solution wrapping (Group II, N=11)
Trial: 23207562
Drug: 2 cc
RxNorm normalized name: Bag Reclosable 2 cc 2X8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cc NG injection (Group III, N=10)
Trial: 23207562
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (Group IV, N=10)
Trial: 15752663
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (10 mg once a day from day 5 to day 25)
Trial: 15752663
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (10 mg once a day from day 8 to day 25)
Trial: 12228784
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) plus ASA
Trial: 1978689
Drug: Tryptophan (TRP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (TRP), up to 6 g/day, administered for 25-35 days
Trial: 686893
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral neomycin and erythromycin base
Trial: 31673828
Drug: Chronic peritoneal
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic peritoneal dialysis with concurrent colostomy
Trial: 24938534
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast (SY) 200 or 285 μg/day
Trial: 24938534
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast (SY) high-dose
Trial: 24938534
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast (SY) low-dose
Trial: 24938534
Drug: Selenomethionine (SeMet)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (SeMet) 200 μg/day
Trial: 17895968
Drug: Leading sports
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leading sports drink (G)
Trial: 8220939
Drug: misoprostol 400-800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 400-800 micrograms daily
Trial: 3806169
Drug: Adjuvant methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant methotrexate (MTX) started at 40 mg/m2 and escalated by 10 mg/m2 weekly, with four doses preoperatively, four doses postoperatively before radiation therapy, and eight doses post-radiation therapy.
Trial: 31138085
Drug: NfL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NfL levels (measured using Single Molecule Array technology)
Trial: 24191893
Drug: 750 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day probucol plus 160 mg/day valsartan
Trial: 24191893
Drug: 160 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/day valsartan
Trial: 20601912
Drug: Silicone hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone hydrogel lenses with multipurpose solutions
Trial: 12946081
Drug: Manual‐assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual‐assisted cognitive behaviour therapy (MACT)
Trial: 1303775
Drug: Cetirizine (Zyrtec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (Zyrtec 10 mg/day)
Trial: 2864486
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg zinc per day as zinc acetate
Trial: 3623260
Drug: Calcium (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (375 mg/day) and vitamin D (1,200 IU/day) supplementation
Trial: 19236727
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg (Eso20)
Trial: 19236727
Drug: Pectin‐based raft‐forming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin‐based raft‐forming agent (PRA)
Trial: 16434738
Drug: Xylitol 6.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol 6.88 g/day (G3)
Trial: 16434738
Drug: Xylitol 10.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol 10.32 g/day (G4)
Trial: 10679534
Drug: Active intervention
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intervention (asthma education and optimisation of drug therapy)
Trial: 9333148
Drug: Zidovudine alone
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine alone or in combination with the immunogen
Trial: 8222665
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ascorbic acid taken 1/2 hour before OC intake
Trial: 8222665
Drug: Combination monophasic
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination monophasic oral contraceptive without ascorbic acid
Trial: 2429800
Drug: Cimetidine, 4
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 4 mg/kg, plus placebo
Trial: 2429800
Drug: Chlorpheniramine, 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 0.1 mg/kg, plus placebo
Trial: 29727369
Drug: High-illuminance blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-illuminance blue light therapy
Trial: 20214175
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1%/benzoyl peroxide 5% gel (BPO/C)
Trial: 20214175
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2%/tretinoin 0.025% gel (T/C)
Trial: 10626316
Drug: Risk factor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factor-based cognitive behavioral therapy
Trial: 10626316
Drug: Refusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refusers of therapy
Trial: 4028625
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic system of scopolamine (TTS-S)
Trial: 4028625
Drug: Transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo (TD-P)
Trial: 7288807
Drug: (+)-isomer of
RxNorm normalized name: hexadecene (mixed isomers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-isomer of tranylcypromine at doses below 3 mg/day
Trial: 20385894
Drug: Infiltration, physiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration, physiotherapy, or medication
Trial: 17368065
Drug: Medical product
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Apollo Medical Products Disinfecting Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical product (with or without LNAA supplements)
Trial: 15837702
Drug: OXAFAFU high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXAFAFU high dose (hd)
Trial: 15837702
Drug: OXAFAFU low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXAFAFU low dose (ld)
Trial: 15837702
Drug: OXAFAFU (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXAFAFU (both doses)
Trial: 8073391
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium (HEP)
Trial: 2563788
Drug: Hepatitis-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis-B vaccine + 7 monthly injections of HB immunoglobulin (HBIg)
Trial: 2563788
Drug: Hepatitis-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis-B vaccine + 1 HBIg injection at birth
Trial: 2563788
Drug: Hepatitis-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis-B vaccine only
Trial: 2563788
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for both vaccine and HBIg
Trial: 31006122
Drug: Intra-articular triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular triamcinolone acetonide (20 mg in both tarsocrural joints, total 40 mg/horse)
Trial: 31006122
Drug: Intramuscular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular triamcinolone acetonide (40 mg)
Trial: 27060379
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (Danish strain 1331 SSI)
Trial: 22969980
Drug: PEG 4000
RxNorm normalized name: PEG 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4000 (20 g/day)
Trial: 22969980
Drug: Lactulose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (15 ml/day)
Trial: 1775598
Drug: Fluoxetine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine at 20 mg/day for at least 8 weeks
Trial: 25349205
Drug: AST-120 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (9 g/d)
Trial: 25208597
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 20 mg tadalafil
Trial: 25208597
Drug: Continuous dose
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dose of 5 mg tadalafil each morning for seven consecutive days
Trial: 22647399
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus cognitive behavioral therapy sessions, psycho-educational sessions for family members, and case management
Trial: 17900265
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ebastine
Trial: 1827340
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (IVS)
Trial: 518806
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation of dichloralphenazone and paracetamol (Paedosed)
Trial: 518806
Drug: i.m. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. morphine and atropine
Trial: 31644357
Drug: pTVG-HP co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTVG-HP co-administered intradermally with 200 μg GM-CSF adjuvant
Trial: 31644357
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg GM-CSF alone
Trial: 25930144
Drug: SG1002 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG1002 (400 mg)
Trial: 25930144
Drug: SG1002 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG1002 (400 mg and 800 mg)
Trial: 25930144
Drug: SG1002 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG1002 (all doses)
Trial: 23672597
Drug: Jiangtang Xiaozhi
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangtang Xiaozhi (3 capsules three times daily for 16 weeks)
Trial: 15482360
Drug: 0.5 microg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microg/kg/min GTN infusion
Trial: 11490238
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg exisulind twice daily for 12 months
Trial: 17405568
Drug: ACE-inhibitors
RxNorm normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitors
Trial: 2718479
Drug: Clidinium bromide
RxNorm normalized name: Clidinium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clidinium bromide 5 mg + Magnesium citrate
Trial: 2718479
Drug: Clidinium bromide
RxNorm normalized name: Clidinium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clidinium bromide 5 mg + Placebo liquid
Trial: 2718479
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule + Magnesium citrate
Trial: 2718479
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule + Placebo liquid
Trial: 340138
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg mefenamic acid
Trial: 340138
Drug: 32.5 mg
RxNorm normalized name: phenol 32.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32.5 mg dextropropoxyphene hydrochloride plus 325 mg paracetamol
Trial: 21148048
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate 50 mg
Trial: 21148048
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate 100 mg
Trial: 21148048
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate 200 mg
Trial: 21148048
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with piperaquine phosphate
Trial: 16440537
Drug: Multifamily Asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifamily Asthma Group Treatment (MFAGT)
Trial: 9222805
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day for ten days
Trial: 9222805
Drug: Doxycycline plus
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline plus ceftriaxone (1 g in two doses for one day)
Trial: 29231617
Drug: Medication combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication combined with acupuncture
Trial: 25420776
Drug: Gestrinone combined
RxNorm normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone combined with ultrasound-guided aspiration and ethanol injection
Trial: 25420776
Drug: Ultrasound-guided aspiration
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided aspiration and ethanol injection
Trial: 21685354
Drug: Emergent literacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergent literacy intervention consisting of eighteen 30‐min lessons delivered twice weekly to small groups of children.
Trial: 11098560
Drug: Amiodarone or
RxNorm normalized name: amiodarone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone or new class III agents (e.g., Dofetilide)
Trial: 8775936
Drug: Antiarrhythmic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agents
Trial: 9328156
Drug: Clodronate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (300 mg/day i.v. for 5 days followed by 1.6 g/day orally for 12 months)
Trial: 8104200
Drug: Idazoxan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (mean dose, 120 mg/day) combined with fluphenazine (mean dose, 28 mg/day)
Trial: 4042078
Drug: Ethyl loflazepate
RxNorm normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl loflazepate 2 mg
Trial: 4042078
Drug: Ethyl loflazepate
RxNorm normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl loflazepate 4 mg
Trial: 4042078
Drug: Ethyl loflazepate
RxNorm normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl loflazepate 6 mg
Trial: 4042078
Drug: Ethyl loflazepate
RxNorm normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl loflazepate 8 mg
Trial: 28984097
Drug: Intraoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative epidural infusion started preoperatively and maintained throughout
Trial: 28984097
Drug: Postoperative initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Postoperative initiation of epidural infusion after neurological examination
Trial: 27655371
Drug: Frontal electromyographic
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal electromyographic (EMG) biofeedback associated with prophylactic pharmacological therapy
Trial: 27655371
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment alone (Control Group)
Trial: 20601737
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g/kg
Trial: 15647411
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg oral suspension
Trial: 15647411
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg oral suspension (hemodialysis-dependent subjects)
Trial: 14512128
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray (BANS) - 64-microg total dose (one 32-microg spray per nostril)
Trial: 14512128
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray (BANS)
Trial: 14512128
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FPNS) - 200-microg total dose (two 50-microg sprays per nostril in study 1) and 100-microg total dose (one 50-microg spray per nostril in study 2)
Trial: 10580711
Drug: Pulsed high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed high-frequency electromagnetic field (EMF) exposure (900 MHz; maximum specific absorption rate 1 W/kg) during night-time sleep